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SUMMARY
Mitochondria house metabolic pathways that impact most aspects of cellular physiology. While 
metabolite profiling by mass spectrometry is widely applied at the whole-cell level, it is not 
routinely possible to measure the concentrations of small molecules in mammalian organelles. We 
describe a method for the rapid and specific isolation of mitochondria, which we use in tandem 
with a database of predicted mitochondrial metabolites (“MITObolome”) to measure the matrix 
concentrations of greater than 100 metabolites across various states of respiratory chain (RC) 
function. Disruption of the RC revealed extensive compartmentalization of mitochondrial 
metabolism and signatures unique to the inhibition of each RC complex. Pyruvate enables the 
proliferation of RC-deficient cells, but had surprisingly limited effects on matrix contents. 
Interestingly, despite failing to restore matrix NADH/NAD balance, pyruvate did increase 
aspartate, likely through the exchange of matrix glutamate for cytosolic aspartate. We demonstrate 
the value of mitochondrial metabolite profiling and describe a strategy applicable to other 
organelles.
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eToc Blurb
Metabolite profiling of intact mammalian mitochondria captures dynamics of mitochondrial 
metabolism not revealed by whole cell analysis.
INTRODUCTION
A hallmark of eukaryotic life is the membrane-bound organelles that compartmentalize 
specialized biochemical pathways within the cell. Enclosed by both outer and inner 
membranes, mitochondria carry out many essential metabolic processes, such as ATP 
generation by the respiratory chain (RC) (Wallace, 2013), aspartate synthesis by matrix 
aminotransferases (Birsoy et al., 2015; Cardaci et al., 2015; Safer, 1975; Sullivan et al., 
2015), and long-chain fatty acid catabolism by the beta-oxidation pathway (Vianey-Liaud et 
al., 1987). Consistent with the critical role of mitochondria in maintaining cellular 
homeostasis, dysfunction of mitochondrial enzymes often leads to disease (Wallace, 2013).
Despite the importance of mitochondrial metabolism to cellular physiology, methods for 
systematically interrogating the polar metabolite contents of mitochondria in mammalian 
cells are limited. In recent years, metabolite profiling of entire cells and tissues by mass 
spectrometry (MS) has greatly improved our understanding of metabolism by allowing for 
the simultaneous analysis of hundreds of metabolites from one sample. Such large-scale 
assessments enable the characterization of entire metabolic networks, which is often 
necessary to understand the effects of a perturbation on cellular metabolism (Cacciatore and 
Loda, 2015). Because mitochondria constitute a small fraction of cellular contents, whole-
cell profiling is likely inadequate for monitoring changes within the mitochondrial matrix.
Several challenges hamper the application of metabolite profiling to subcellular organelles, 
such as mitochondria. Standard techniques for purifying mitochondria can take hours to 
complete, leading to the significant loss of metabolites because solute transporters and 
enzymes can have residual activity even at low temperatures (Bowsher and Tobin, 2001; 
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Matuszczyk et al., 2015; Ross-Inta et al., 2008). Commercially available kits for antibody-
based isolation of mitochondria are technically less cumbersome than other methods but 
utilize long immunopurification and wash steps (Miltenyi, 2011). Abbreviated centrifugation 
protocols, selective membrane permeabilization, and non-aqueous fractionation all improve 
the speed of the workflow and have provided important insights into the metabolism of 
subcellular compartments, but the resulting mitochondrial preparations can be contaminated 
with cytosolic material, as well as other organelles, such as endoplasmic reticuli and 
lysosomes (Berry et al., 1991; Berthet and Baudhuin, 1967; Bestwick et al., 1982; Fly et al., 
2015; Linskens et al., 2012; Matuszczyk et al., 2015; Roede et al., 2012; Tischler et al., 
1977). Furthermore, components of traditional organellar isolation buffers (e.g., sucrose) can 
severely interfere with MS-based metabolite profiling (Roede et al., 2012). Thus, the 
interrogation of matrix metabolites in a straightforward, robust, and specific manner remains 
a significant challenge to the study of mitochondrial physiology.
To address this, we developed a new method that combines rapid immunocapture of epitope-
tagged mitochondria with metabolite profiling by liquid chromatography and mass 
spectrometry (LC/MS). The isolation of mitochondria and extraction of their metabolites 
occurs within minutes of cellular homogenization and has greatly improved speed and 
specificity over prior approaches. Using this technique, we generated a quantitative resource 
containing the matrix concentrations of more than 100 polar metabolites in cells under 
various states of RC function. This resource enabled us to study the biology of pyruvate, 
which can reprogram cellular metabolism and mitigate the anti-proliferative effects of RC 
dysfunction in a manner that is poorly understood at the level of the mitochondrial matrix. 
Our work exemplifies the power of this quantitative resource for studying mitochondrial 
biology and provides a methodological framework for interrogating the metabolite contents 
of other subcellular compartments.
RESULTS AND DISCUSSION
A method for the rapid and specific isolation of intact mitochondria
To faithfully profile matrix metabolites, one needs a technique that is both rapid and capable 
of effectively separating mitochondria from other subcellular components. Existing methods 
do not adequately address both of these requirements. In addition, traditional mitochondrial 
isolation buffers contain high concentrations of solutes (e.g., sucrose) that are not suitable 
for LC/MS-based metabolomics because of the sensitivity of LC/MS instruments to small 
molecule contaminants.
To isolate mitochondria rapidly and specifically, we developed an immunopurification (IP) 
strategy utilizing outer mitochondrial membrane proteins as handles for immunocapture, 
which enabled metabolite extraction from mitochondria in less than 12 minutes following 
cellular homogenization. Instead of using an endogenous outer membrane protein, we chose 
an epitope-tagged recombinant protein to be the IP handle because of the high sensitivity 
and specificity of various epitope-tags and their cognate antibodies. Three epitope tags were 
placed in tandem on the N-terminus of EGFP fused to the well-characterized, outer 
mitochondrial membrane localization sequence of OMP25 (Figure S1A) (Nemoto and 
Camilli, 1999), and different tagging systems were tested for their ability to immunocapture 
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mitochondria within 3.5 minutes. In HeLa cells, the epitope-tagged protein properly 
localized to mitochondria, as detected by the complete overlap of the EGFP signal with the 
established mitochondrial marker MitoTracker Deep Red FM (Figure 1A). Initial attempts to 
isolate mitochondria using a FLAG-based magnetic bead system commonly employed for 
protein IPs led to extremely poor yields (Figure S1B). As the FLAG epitope-antibody 
pairing is relatively high-affinity, we suspected that the major issue was the nature of the 
beads rather than the epitope tag itself. FLAG antibody-conjugated beads are relatively large 
(~50 μm in diameter) but are made of a porous agarose matrix, which enables them to 
circumvent the reduced surface area associated with increased bead size. However, as the 
average diameter of the agarose pores and mitochondria are ~30 nm and ~500 nm, 
respectively, the majority of mitochondrial capture was probably limited to the surface of the 
beads, in which case reducing bead size would lead to improved yields. Consistent with this, 
switching to a 3XHA-EGFP-OMP25 construct (HA-MITO) and the smaller cognate beads 
(non-porous, ~1 μm in diameter) led to dramatically improved yields in both protein (Figure 
S1B) and metabolite content (Figure S1C), while also preventing extra-mitochondrial 
metabolites from becoming trapped within the bead matrix.
In addition to the challenges of capturing mitochondria, the sensitivity of LC/MS 
instruments to small molecule contaminants necessitated extensive optimization of isolation 
conditions. In initial experiments, we found that many components of traditional 
mitochondrial isolation buffers (e.g., sucrose, HEPES) significantly distorted LC/MS-based 
analyses, often leading to the complete loss of the signal for certain metabolites (Figure 
S1D). Prior work has demonstrated that KCl-based buffers can allow for the isolation of 
coupled mitochondria capable of supporting a membrane potential (Corcelli et al., 2010). As 
such, we developed an LC/MS-compatible buffer consisting only of KCl and KH2PO4 
(“KPBS”), which had significantly improved performance (Figure S1E).
Utilizing our LC/MS-compatible isolation conditions and cells expressing 3XMyc- EGFP-
OMP25 (Control-MITO) or HA-MITO, we developed a workflow for the quantitative 
interrogation of matrix metabolite concentrations (Figure 1B), the complete details of which 
are described in the Methods and Resources. In brief, we quantified the moles of a matrix 
metabolite in the IP material by LC/MS-based metabolomics, and the total matrix volume 
per cell by confocal microscopy. Immunoblot analyses of a mitochondrial marker in whole-
cell lysates and the IP material gave the number of whole-cell equivalents present in the 
latter, which we combined with our microscopy-based measurements to determine the 
matrix volume of the isolated mitochondria. It is important to note that defining the true free 
space in the mitochondrial matrix is difficult because of its physical properties and so we 
used the traditional estimate of matrix space determined by electron microscopy (Gerencser 
et al., 2012; Srere and Sumegi, 1986). Thus, using both the moles of a metabolite and the 
associated matrix volume, we could derive a corresponding concentration.
Importantly, mitochondria isolated using our workflow exhibited good integrity and purity. 
Following isolation from cells incubated with MitoTracker Deep Red FM, mitochondria 
attached to beads still retained the dye, suggesting that the organelles were intact (Figure 
1C). Immunoblot analyses of markers for mitochondria and other subcellular compartments 
revealed that our approach had significantly less contamination compared to differential 
Chen et al. Page 4
Cell. Author manuscript; available in PMC 2017 August 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
centrifugation methods that are optimized for speed (Figure 1D) (Bestwick et al., 1982; 
Bogenhagen and Clayton, 1974). The residual LAMP2 signal in the IP material from both 
Control-MITO and HA-MITO cells likely reflects binding of free, non-lysosomal LAMP2 
protein and not binding of lysosomes, as we did not detect cathepsin C, a protein found in 
the lysosomal lumen, in the IP material (unpublished data) or cystine, a lysosomal 
metabolite, in isolated mitochondria (Table S1).
To quantitatively assess the integrity of purified mitochondria, we used a protein and 
metabolite marker to calculate how much of the mitochondrial material present in whole-
cells was captured in each IP (e.g., yield) (Figure 1E). Both the enzyme citrate synthase (CS) 
and the metabolite coenzyme A (CoA) predominantly reside in the mitochondrial matrix, 
with only 10–20% of cellular CoA being extra-mitochondrial (Idell-Wenger et al., 1978; 
Williamson and Corkey, 1979). Consistent with this, measurements of yield using either CS 
or CoA gave similar results, again demonstrating that the isolated mitochondria were intact, 
retaining both the protein and small molecule markers to equal degrees (Figure 1E). The 
isolated mitochondria also retained a significant amount of the membrane-potential sensitive 
dye, TMRM, as well as its de-esterified intracellular form, TMR (Figure S1F). Importantly, 
treatment of cells with the uncoupler FCCP led to substantial loss of the dyes in 
mitochondria, demonstrating that the TMRM and TMR in isolated mitochondria were 
indeed membrane-potential responsive. Collectively, these data show that our method 
enables rapid and specific isolation of intact mitochondria for metabolite profiling.
Identities and concentrations of matrix metabolites in human mitochondria
Because of the technical limitations of prior techniques, the identities and concentrations of 
polar, matrix metabolites in human mitochondria remain largely unknown. To address this, 
we began by generating a list of all predicted mitochondrial metabolites (the 
“MITObolome”) by taking the known substrates, products, and cofactors of all 
mitochondrial enzymes and small molecule transporters (Figure 2A). Using the 
MITObolome, we assembled a library of 132 chemical standards for the absolute 
quantification of metabolites within the mitochondrial matrix and whole-cells (Figure 2A, 
Table S1). The Methods and Resources section describes in detail how the MITObolome and 
the final profiling set were assembled.
We quantified the concentrations of both whole-cell and mitochondrial samples using 
standard curves of every metabolite in the final profiling set (Table S1). Only total 
concentrations of metabolites were measured as distinguishing between free and bound 
populations remains a challenge in metabolomics. Reassuringly, comparisons of matrix 
concentrations of biological replicates demonstrated a high degree of correlation (Figure 
2B). In addition, there was an excellent correlation between samples prepared using the 
normal workflow and a workflow lengthened by 4 minutes, suggesting that there was not 
substantial distortion of the matrix metabolite profile in the time frame of our isolations, 
although it is difficult to know how mitochondria behave at time points earlier than our 
shortest isolations (Figure S2A). Various cofactors and redox pairs critical for mitochondrial 
reactions, such as NAD, NADH, FAD, NADP, GSH, GSSG, and SAM, were all found in 
mitochondria (Figure 2C). Metabolites involved in other mitochondrial processes, such as 
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the TCA cycle, energy production, and fatty-acid metabolism, were present as well. 
Importantly, we did not observe signs of significant contamination from other subcellular 
compartments because various metabolites not expected to be abundant in mitochondria, 
such as cystine (lysosomes), sedoheptulose 7-phosphate, and fructose 1,6-bisphosphate 
(cytosol) were not present at levels above background. With regards to the accuracy of our 
measurements, our quantification of the matrix NADH/NAD ratio (0.009) agrees with prior 
studies that indirectly estimated matrix NADH/NAD ratios to span 0.006–0.125, depending 
on the cell type examined (Erecinska et al., 1978; Nishiki et al., 1978). Taken together, these 
data indicate that our LC/MS-based workflow can be used to quantitatively study the 
metabolic landscape of the mitochondrial matrix.
Concentrations of most metabolites within the mitochondrial matrix were generally lower 
than corresponding measurements made at the whole-cell level (Figure 2C and Figure S2B). 
The most abundant metabolites were aspartate (1600 μM), phosphocholine (1471 μM), GSH 
(1374 μM) and NAD (818 μM), each of which participate in distinct metabolic processes 
(Figure 2C). In contrast, the least abundant were methylthioadenosine (31 nM), inosine (26 
nM), and urate (17 nM), all metabolites involved in nucleotide metabolism. As a whole, 
matrix concentrations spanned a wide range of values, even within the same family of 
metabolites, underscoring the diversity of the metabolic space within mitochondria.
One particularly diverse class of matrix metabolites is amino acids, which participate in both 
metabolic reactions and the synthesis of the 13 mitochondrially-encoded proteins required 
for RC activity (Elo et al., 2012). The majority of proteinogenic amino acids were found in 
mitochondria (Figure 2C and Tables S1–S3), with the most abundant being aspartate (1600 
μM), alanine (327 μM), and histidine (82 μM) (Figure 2C). Although the mitochondrial 
abundance of different amino acids will likely vary between different cell types, the high 
concentration of aspartate agrees with recent findings demonstrating that a critical role for 
mitochondria in supporting cell proliferation is aspartate synthesis (Birsoy et al., 2015; 
Sullivan et al., 2015).
We also examined the relationships between the KMAmino acid values of different 
mitochondrial aminoacyl-tRNA synthetases and the concentrations of their cognate amino 
acids. For example, the KMAsp of human mitochondrial aspartyl-tRNA synthetase is 1.5 μM 
(Messmer et al., 2009), while the average, baseline matrix concentration of aspartate across 
all experiments was 1113 μM (Tables S1–S3). In the case of aspartate, the matrix 
concentration is maintained well above the KMAsp of the aspartyl-tRNA synthetase, likely 
ensuring that fluctuations in the abundance of aspartate do not affect charging of the cognate 
tRNAs. Yet one interesting instance where this was not the case is phenylalanine. The 
average, baseline matrix concentration of phenylalanine across all experiments was 24.2 μM 
(Tables S1–S3). However, the KMPhe of the mitochondrial phenylalanyl-tRNA synthetase 
(FARS2) is 7.3 μM. Mutations in FARS2 can reduce levels of mitochondrially-encoded 
proteins and cause fatal epileptic mitochondrial encephalopathy by decreasing the affinity of 
the FARS2 enzyme for its various substrates (e.g., ATP, tRNA, phenylalanine). In contrast to 
other pathogenic mutations, a D391V substitution in FARS2 does not substantially alter 
KMATP and KMtRNA, but increases the KMPhe of FARS2 from 7.3 μM to 20.9 μM (Elo et al., 
2012). Based on our measurements of matrix phenylalanine concentrations, this could lead 
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to inefficient charging of mitochondrial tRNAPhe and reduced mitochondrial protein 
synthesis. These findings thus provide additional insight into the pathogenic basis of the 
D391V form of FARS2 and exemplify how our quantitative profile of mitochondria can be 
used with in vitro characterizations of mitochondrial proteins.
To complement our MITObolome-based approach of profiling mitochondria, we also 
performed highly-targeted and untargeted LC/MS-based metabolomics. Using a tSIM 
(targeted selected ion monitoring) scan, we quantified additional nucleotide species in 
mitochondria that were difficult to detect using a standard full scan (Table S1). In addition, 
using untargeted metabolomics, we uncovered numerous molecules not predicted to be 
mitochondrial based on the MITObolome (Table S1). As untargeted metabolomics does not 
provide definitive metabolite identification, validation of peaks is critical for proper data 
analysis. By matching the characteristics of the peak from our untargeted analysis with those 
of the corresponding chemical standard, we identified ADP-ribose as a metabolite not 
previously assigned to the mitochondria based on the databases we have examined (Table 
S1). ADP-ribose is a substrate for poly(ADP-ribosylating) enzymes, which localize to 
mitochondria and may maintain the integrity of mitochondrial DNA (Scovassi, 2004). Taken 
together, these results demonstrate the utility of our targeted and untargeted approaches for 
studying the metabolite contents of mitochondria.
Whole-cell analyses do not capture the dynamics of mitochondrial metabolism
Comprised of Complexes I–V, the RC oxidizes NADH and FADH2 to generate a proton 
gradient that drives the rotation of Complex V and the synthesis of ATP (Figure 3A). 
Inherited defects in RC complexes cause various forms of mitochondrial disease (Wallace, 
2013). However, our understanding of the metabolic consequences of RC pathology is 
incomplete, especially at the mitochondrial level.
To model different disease states, we treated cells with penetrant doses of piericidin 
(Complex I inhibitor), antimycin (Complex III inhibitor), and oligomycin (Complex V 
inhibitor) (Figure 3A and Table S2). While the whole-cell responses to these inhibitors have 
been previously studied (Birsoy et al., 2015; Chen et al., 2014; Mullen et al., 2012; Shaham 
et al., 2010; Sullivan et al., 2015), the alterations in matrix metabolites have not. Because of 
the compartmentalized nature of mitochondria, matrix metabolites can be regulated in 
unique ways and be present at levels much lower than those in other sub-cellular 
compartments. For these reasons, we hypothesized that whole-cell studies do not accurately 
capture the dynamics of matrix metabolites during RC dysfunction.
In cells treated with each of the three inhibitors, the metabolite profiles of whole-cells and 
the mitochondrial matrix were highly different (Figures 3B and 3C). For some metabolites, 
such as aspartate, we observed similar trends in both, but the extent of the change was 
generally greater in the matrix (Figure 3B). For other metabolites, such as 
phosphoenolpyruvate (PEP) and saccharopine, the differences between whole-cells and the 
matrix were dramatic (Figures 3D and 3E). In these cases, direct interrogation of 
mitochondria uncovered alterations in critical metabolic processes that would have gone 
undetected using whole-cell metabolomics.
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Two distinct pathways, glycolysis and gluconeogenesis, generate PEP in mammalian cells. 
Enolase catalyzes the formation of PEP from 2-phosphoglycerate in the cytosol, and PEP 
carboxykinase (PEPCK) generates PEP from oxaloacetate in the matrix and cytosol. The 
mitochondrial PEPCK (m-PEPCK) reaction is a rate-limiting step in the gluconeogenic 
pathway. However, it has been difficult to study mitochondrial PEPCK due to the substantial 
contribution of cytosolic pools of PEP to the whole-cell signal (Stark et al., 2014). Matrix 
PEP levels dropped significantly across all three forms of RC dysfunction, with the severity 
of the phenotype correlating well with the relative change in matrix aspartate, a proxy for the 
m-PEPCK substrate, oxaloacetate (Ke et al., 2015) (Figures 3B and 3D). Underscoring the 
importance of directly profiling mitochondria, whole-cell PEP levels did not significantly 
change during inhibition of the RC (Figure 3D). Collectively, these data demonstrate that RC 
dysfunction leads to reduced oxaloacetate, a TCA cycle metabolite, and consequently a 
dramatic impairment of m-PEPCK activity, an important step in gluconeogenesis. These 
findings are in line with prior work arguing that m-PEPCK also links TCA cycle activity to 
gluconeogenesis through the enzyme’s dependence on GTP, which is formed by the TCA 
cycle member, succinate thiokinase (Stark et al., 2009).
A similarly compartmentalized defect occurred in the lysine degradation pathway during all 
forms of RC dysfunction, as evidenced by the accumulation of matrix saccharopine (Figure 
3E). The matrix enzyme, aminoadipate-semialdehyde synthase (AASS) metabolizes 
saccharopine, a breakdown product of lysine, in an NAD-dependent manner (Markovitz et 
al., 1984). Accumulation of NADH within the matrix likely leads to inhibition of AASS 
activity during RC dysfunction (Figure 3B). Similar to PEP, saccharopine did not 
significantly change on the whole-cell level, likely due to the cytosolic pool of saccharopine 
being larger than the matrix pool (Figure 3E). However, in contrast to the production of PEP 
in multiple subcellular compartments, only mitochondria generate saccharopine (Kanehisa 
and Goto, 2000). Thus, whole-cell studies can fail to detect a change in matrix metabolism 
even when the participating metabolite has a purely mitochondrial origin. Taken together, 
these data demonstrate that there is substantial compartmentalization of metabolic changes 
during RC dysfunction that necessitates profiling at the matrix level.
Extensive compartmentalization of core redox and anti-oxidant metabolism in cells with 
RC inhibition
Redox balance and anti-oxidant defense are two core mitochondrial processes critical for 
maintaining matrix homeostasis and regulated by the ratios of NADH/NAD and GSH/
GSSG, respectively (Wheaton et al., 2014). We were particularly interested in the behavior 
of these processes as it has been speculated that during RC dysfunction the mitochondrial 
changes in NADH/NAD and GSH/GSSG are likely distinct from those seen in whole-cells 
(Van Vranken and Rutter, 2015; Wheaton et al., 2014). Consistent with this, there were 
dramatic differences in the degree of NADH/NAD imbalance in whole-cells and the 
mitochondrial matrix during RC dysfunction (Figure 3F). Whole-cell NADH/NAD ratios 
increased during RC dysfunction by a maximum of 2.3-fold upon Complex III inhibition 
and did not increase at all during Complex V inhibition. In contrast, all three inhibitors 
significantly elevated matrix NADH/NAD ratios, with Complex I inhibition increasing the 
NADH/NAD ratio ~77-fold. The smaller changes in whole-cell NADH/NAD ratios during 
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RC blockade are consistent with matrix NADH being a small portion of the whole-cell pool 
(Table S2). In addition, while RC dysfunction largely cripples the mitochondrial axis of 
NAD regeneration, lactate dehydrogenase can still replenish cytosolic NAD, thereby 
mitigating cytosolic NADH/NAD imbalance.
A major consequence of RC dysfunction is a decreased level of aspartate, which 
mitochondria produce primarily through a series of NAD-dependent reactions (Birsoy et al., 
2015; Safer, 1975; Sullivan et al., 2015). As such, we hypothesized that there should be a 
relationship between matrix NADH/NAD ratios and aspartate concentrations across different 
states of RC function. Indeed, there was an excellent correlation between the log10-
transformed values of matrix aspartate and NADH/NAD, which demonstrates that the 
relationship between aspartate and the NADH/NAD ratio can be modeled as a power 
function (Figure 3G). Consistent with this, even a relatively mild increase in the 
NADH/NAD ratio (e.g., oligomycin treatment) could account for the majority of the loss in 
matrix aspartate, suggesting that aspartate synthesis is quite sensitive to changes in matrix 
NADH/NAD redox balance.
In addition to NAD and NADH, we also examined the behavior of GSH and GSSG, another 
redox pair critical for mitochondrial function and one often used as a metric for oxidative 
stress. In contrast to whole-cells, inhibition of either Complex I or III significantly increased 
the matrix GSH/GSSG ratio (Figure 3H), demonstrating that disruption of RC function can 
lead to a state in which there is less oxidative stress in the matrix. These data agree with 
models in which RC activity generates a significant amount of reactive oxygen species in 
mitochondria (Wheaton et al., 2014), but may also reflect a relationship between 
NADH/NAD and GSH/GSSG ratios that is mediated through mitochondrial 
transhydrogenases, which can utilize NADH to generate NADPH, a redox molecule critical 
for driving GSH formation (Mullen et al., 2012). Collectively, these results reveal how 
profiling the metabolite contents of mitochondria can even uncover new information about 
well-studied core processes, such as redox balance and anti-oxidant defense.
Mitobolomics reveals unique signatures of Complex I, III, and V inhibition
Complexes I, III, and V have non-redundant functions in the RC and defects in each can lead 
to distinct forms of mitochondrial disease (Wallace, 2013). While general features of RC 
dysfunction, such as NADH/NAD imbalance, are well-appreciated, our understanding of the 
metabolic consequences of inhibiting specific RC complexes remains incomplete, 
particularly at the mitochondrial level. To that end, we identified metabolic alterations in the 
matrix that are unique to the inhibition of Complex I, III, or V.
A striking example of such a metabolic signature is the accumulation of acetyl-CoA in the 
matrix of cells with Complex I inhibition, which we did not observe in any other form of RC 
dysfunction (Figure 4A). Whole-cell acetyl-CoA did not recapitulate the changes in matrix 
acetyl-CoA, likely due to the larger extra-mitochondrial pools of acetyl-CoA. Acetyl-CoA 
normally enters the TCA cycle through the action of citrate synthase, an enzyme that 
decreases in activity when the NADH/NAD ratio is high. Although the reason that Complex 
V blockade does not lead to acetyl-CoA accumulation is likely the smaller degree of 
NADH/NAD imbalance, the same cannot be said for Complex III inhibition, which 
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increased the matrix NADH/NAD ratio substantially (Figure 3F). Consistent with 
Complexes I and III altering the matrix NADH/NAD ratio to a comparable degree, both 
forms of RC dysfunction reduced matrix aspartate to a similar extent (Figure 3G). However, 
one of the distinguishing features of Complex III blockade is that it also impairs the 
regeneration of FAD. The first step of fatty acid oxidation, which contributes significantly to 
matrix acetyl-CoA pools, requires FAD (Vianey-Liaud et al., 1987). As such, acetyl-CoA 
likely does not accumulate upon Complex III inhibition because it cannot be generated in 
sufficient amounts. While fatty acid oxidation also requires NAD to generate acetyl-CoA 
(Vianey-Liaud et al., 1987), it is possible that residual flux through the NAD-dependent step 
during Complex I inhibition can still lead to acetyl-CoA accumulation. There is precedent 
for this as succinate accumulates during Complex III inhibition despite reduced activity of 
the upstream enzyme, alpha-ketoglutarate dehydrogenase (Mullen et al., 2012). Interestingly, 
prior work has shown that excess acetyl-CoA can lead to non-enzymatic acetylation of 
mitochondrial proteins, a pathological process countered by the mitochondrial deacetylase, 
SIRT3 (Wagner and Payne, 2013). Our findings thus suggest that Complex I inhibition may 
impose a greater burden on the SIRT3 system than other forms of RC dysfunction.
It is well appreciated that Complex III inhibition leads to the accumulation of succinate in 
cells (Mullen et al., 2012). Interestingly, while succinate behaved as expected at the whole-
cell level, it did not accumulate appreciably in the matrix, suggesting that excess succinate is 
rapidly exported into the cytosol (Figure 3B). We did however observe a substantial 
accumulation of choline and loss of betaine in the mitochondrial matrix, which was unique 
to Complex III inhibition (Figure 4B). Similar trends were observed in whole-cells, although 
to much lesser degrees. This pattern of metabolic changes likely reflects a decrease in the 
activity of choline dehydrogenase, a matrix enzyme dependent on FAD. These data 
demonstrate that only Complex III inhibition decreases mitochondrial synthesis of betaine, 
which can play an important role in the cellular maintenance of the SAM-SAH cycle of 
methylation (Kanehisa and Goto, 2000).
Inhibition of Complex V led to mitochondrial abnormalities also seen with inhibition of 
Complexes I and III (e.g., loss of matrix aspartate) but generated a distinctive distribution of 
TCA cycle metabolites within the matrix that was not seen on the whole-cell level (Figures 
4C and 4D). Indeed, matrix metabolites on opposite ends of the cycle accumulated (e.g., 
alpha-ketoglutarate, malate) and decreased dramatically (e.g., fumarate). This is in contrast 
to inhibition of Complexes I and III, which caused a general decrease of TCA cycle 
components from alpha-ketoglutarate onwards (Figures 4C and 3B) and suggests that there 
is greater oxidative TCA cycle activity during Complex V inhibition.
Although we have highlighted a few notable examples to exemplify the utility of our 
approach, there were many other interesting phenomena specific to certain forms of RC 
dysfunction. For example, Complex I inhibition led to a massive increase in the matrix 
acetylcarnitine/carnitine ratio (> 250-fold), compared to the other forms of RC blockade (< 
20-fold), whereas only Complex III inhibition significantly increased levels of carbamoyl 
aspartate (Figures S3A and S3B). Future work will be needed to fully appreciate the impacts 
of these metabolic changes during RC pathology. More generally though, these studies 
reveal that specific states of RC dysfunction lead to unique alterations in matrix metabolites.
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Amelioration of RC dysfunction with pyruvate increases matrix aspartate without 
restoration of the matrix NADH/NAD ratio
Pyruvate has been known for decades to suppress the anti-proliferative effects of RC 
dysfunction (Harris, 1980; King and Attardi, 1989). Recent work shows that pyruvate 
supplementation during RC dysfunction leads to regeneration of NAD and induction of 
aspartate synthesis in the cytosol (Birsoy et al., 2015; Sullivan et al., 2015). Given the ability 
of pyruvate to substantially alter cytosolic metabolism, we asked whether it could similarly 
reverse the mitochondrial defects associated with RC dysfunction.
Inhibition of Complex I, III, or V has been shown to reduce aspartate at the whole-cell level 
(Birsoy et al., 2015; Sullivan et al., 2015). To improve our chances of seeing pyruvate-
mediated rescue during the time frame of our treatment conditions, we examined Complex V 
blockade with oligomycin, which causes significant but relatively modest NADH/NAD 
imbalance in the mitochondrial matrix (Figure 3F). Inhibition of Complex V did not increase 
the whole-cell NADH/NAD ratio, but pyruvate did lower NADH/NAD ratios regardless of 
treatment conditions, demonstrating that pyruvate was driving NAD regeneration (Figure 
S4). Consistent with this, pyruvate supplementation significantly rescued whole-cell 
aspartate during Complex V inhibition, but also led to a significant improvement in matrix 
aspartate as well (Figure 5A).
Interestingly, despite the ability of pyruvate to increase NAD regeneration in the cytosol, the 
matrix NADH/NAD ratio did not improve with pyruvate supplementation during Complex V 
inhibition (Figure 5B). In contrast to the relationship between matrix NADH/NAD ratios and 
aspartate in the absence of pyruvate (Figure 3G), this was a unique example in which the 
behavior of aspartate did not correlate well with changes in NADH/NAD balance (Figures 
5A and 5B). Thus, pyruvate can increase matrix aspartate without ameliorating the 
NADH/NAD imbalance caused by RC dysfunction.
Consistent with its inability to correct the matrix NADH/NAD ratio, pyruvate did not 
significantly alter the behavior of metabolites that were substantially changed during 
oligomycin treatment (Figure 5C and Table S3). Indeed, there were good correlations 
between the metabolic profiles of cells treated with oligomycin in the presence and absence 
of pyruvate at the matrix level, as well as the whole-cell level (Figure 5D).
Interestingly, pyruvate supplementation led to reduced glutamate accumulation during 
Complex V blockade (Table S3). Matrix glutamate accumulated in all forms of RC 
dysfunction tested (Figure 3B), likely due to inhibition of the NAD-dependent, 
mitochondrial glutamate dehydrogenases. However, because pyruvate did not restore the 
matrix NADH/NAD ratio (Figure 5B), it is unlikely that redox changes reduced the 
accumulation of glutamate. Taking advantage of our absolute quantification of metabolites, 
we compared the matrix levels of glutamate and aspartate. Interestingly, upon pyruvate 
supplementation, the decrease in the concentration of matrix glutamate was very similar in 
magnitude to the increase in the concentration of matrix aspartate (Figure 5E, Table S3, and 
Methods and Resources for calculations). These findings are consistent with the behavior of 
mitochondrial aspartate-glutamate transporters, which exchange aspartate for glutamate 
(Palmieri, 2013). During RC inhibition in the presence of pyruvate, the accumulation of 
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cytosolic aspartate and mitochondrial glutamate could potentially drive the antiport activity 
of these transporters. We thus suggest that pyruvate improves cytosolic and matrix aspartate 
through two distinct metabolic routes, with the mitochondrial axis not even dependent on 
restoration of the matrix NADH/NAD ratio (Figure 5F).
CONCLUSIONS
The speed and specificity of existing isolation protocols have made it challenging to profile 
the polar metabolite contents of mitochondria in mammalian systems. To address this, we 
developed a new technique that combines high-affinity capture of epitope-tagged 
mitochondria and LC/MS-based metabolomics. This allowed us to generate a quantitative 
resource containing matrix concentrations of more than 100 metabolites under different 
states of RC function, revealing the compartmentalized dynamics of numerous metabolic 
processes. From this work, we find that pyruvate has limited effects on matrix metabolites 
during RC pathology, but can increase matrix aspartate without ameliorating matrix 
NADH/NAD imbalance.
Increasing matrix aspartate is important during RC pathology because mitochondria require 
aspartate to synthesize critical RC components. In states of partial RC dysfunction (e.g., 
Complex I inhibition), residual RC activity preserves key cellular processes, such as de novo 
pyrimidine synthesis (King and Attardi, 1989) and mitochondrial membrane potential 
(Birsoy et al., 2015; Chen et al., 2014). Thus, if pyruvate increased aspartate solely in the 
cytosolic compartment of cells with partial RC dysfunction, then it is possible that the 
existing deficiency in matrix aspartate could lead to decreased mitochondrial protein 
synthesis and further cellular pathology.
Taken together, we believe that this work demonstrates the power of our methodology for 
studying mitochondrial metabolism. The use of epitope-tags to isolate mitochondria allows 
for spatiotemporal control over which cell type one purifies from, a particularly useful 
feature for in vivo metabolic studies. More generally, the relative ease of designing epitope-
tagged handles for different organelles suggests that our strategy can be extended to other 
subcellular compartments, thus allowing for in-depth characterization of organellar 
metabolites in mammalian systems.
METHODS AND RESOURCES
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for reagents may be directed to, and will be fulfilled by the 
corresponding author David M. Sabatini (sabatini@wi.mit.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Generation of cells with epitope-tagged mitochondria—HeLa cells, an established 
human cell line, were originally purchased from ATCC. Their identity was confirmed prior 
to the start of this work through cell line authentication (Duke University DNA Analysis 
Facility).
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Various epitope-tagged constructs were transfected with the retroviral packaging vectors 
Gag-Pol and CMV VSV-G into HEK-293T cells. Media was changed 24 hours after 
transfection. The virus-containing supernatant was collected 48 hours after transfection and 
passed through a 0.45 μm filter to eliminate cells. HeLa cells were infected in media 
containing 8 μg/mL of polybrene and a spin infection was performed by centrifugation at 
~1,100 g for 1 hour. Post-infection, virus was removed and cells were selected with 
blasticidin (10 μg/mL), before being FACS-sorted twice for GFP positivity.
Cell culture conditions—HeLa cells were grown in DME base media containing 10% 
heat inactivated fetal bovine serum, 4 mM glutamine, penicillin, and streptomycin. For all 
experiments, cells were cultured in DME base media, DMEM lacking pyruvate (Sigma), or 
DMEM lacking pyruvate supplemented with 1 mM pyruvate. For each experiment, cells 
were washed once with PBS (-) before being cultured with the indicated media. For 
experiments measuring TMRM and TMR, cells were first cultured for 45 minutes in DME 
base media with TMRM (25 nM) and verapamil (10 μM), which facilitates loading of 
TMRM into cells. Cells were then treated with 100% ethanol (1/1000) or FCCP (10 μM) for 
an additional 30 minutes before processing. For all other experiments using DME base 
media, cells were cultured in normal base media for one hour before processing. For 
experiments comparing the effects of different RC inhibitors, cells were treated for two 
hours with 100% DMSO (1/1000), piericidin (5 μM), antimycin (10 μM), or oligomycin (5 
μM) in DMEM lacking pyruvate. For experiments studying the effects of pyruvate on 
mitochondrial metabolites during Complex V inhibition, cells were treated for two hours 
with 100% DMSO (1/1000) or oligomycin (5 μM) in DMEM lacking pyruvate or DMEM 
lacking pyruvate and supplemented with 1 mM pyruvate.
METHOD DETAILS
Magnetic beads, antibodies, reagents, and constructs—aterials were obtained 
from the following sources: Anti-FLAG M2 magnetic beads (M8823) from Sigma-Aldrich; 
anti-HA magnetic beads (88837) from Thermo Fisher Scientific; antibodies to VDAC 
(4661), CS (14309), RPS6KB1 (2708), GOLGA1 (13192), and CALR (12238) from Cell 
Signaling Technology; antibody to SHMT2 (HPA-020549) from Sigma-Aldrich; antibodies 
to LAMP2 (sc-18822) and LMNA (sc-20680) from Santa Cruz Biotechnology; antibody to 
PEX19 (ab137072) from Abcam; HRP-conjugated anti-mouse and anti-rabbit antibodies 
from Santa Cruz Biotechnology; piericidin A from Enzo Life Sciences; sodium pyruvate, 
polybrene, antimycin A, oligomycin A, FCCP, and verapamil from Sigma-Aldrich; 
blasticidin from Invivogen; and MitoTracker Deep Red FM and TMRM from Thermo Fisher 
Scientific.
Retroviral 3XFLAG-EGFP-OMP25, 3XMyc-EGFP-OMP25, 3XHA-EGFP-OMP25 vectors 
were generated via ligation of fragments PCR-amplified from an EGFP-OMP25 construct 
(Addgene, #38249) (Yoshii et al., 2011) into a pMXs-IRES-blasticidin retroviral vector (Cell 
Biolabs) digested with XhoI and NotI.
Immunoblotting—Protein from lysates were prepared for and resolved by 12% SDS-
PAGE at 100 V, transferred for 2.5 hours at 50 V onto 0.45 μm PVDF membranes, and 
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analyzed by immunoblotting as described previously (Chantranupong et al., 2014). 
Membranes were blocked with 5% nonfat dry milk prepared in TBST (tris-buffered saline 
with Tween 20) for 45 minutes at room temperature, then incubated with primary antibodies 
in 5% milk overnight at 4°C. Primary antibodies to the followi ng proteins were used at the 
indicated dilutions: VDAC (1/1000), CS (1/1000), RPS6KB1 (1/1000), GOLGA1 (1/1000), 
CALR (1/1000), SHMT2 (1/1000), LAMP2 (1/2000), LMNA (1/1000), and PEX19 
(1/1000). Membranes were then washed three times, 5 minutes each, with TBST and 
incubated with the corresponding secondary antibodies in 5% milk (1/5000) for 45 minutes 
at room temperature. Membranes were then washed three more times, 5 minutes each, with 
TBST before being visualized using enhanced chemiluminescence (Thermo Fisher 
Scientific).
Confocal microscopy—For experiments confirming proper localization of the epitope-
tagged protein to mitochondria, ~60,000 HeLa cells expressing different 3XTag-EGFP-
OMP25 constructs were incubated with 6.25 nM – 25 nM MitoTracker Deep Red FM 
(MTDR) (Thermo Fisher Scientific) for one hour. Cells were then fixed with 4% PFA in 
PBS, mounted with anti-fade mounting medium containing DAPI (Vectashield), and imaged 
on an RPI spinning disk confocal microscope (Zeiss) using EGFP, MTDR, and DAPI 
channels. For imaging mitochondria on beads, 4% PFA in PBS was used instead of 80% 
methanol during the mitochondrial IP workflow (see below). Images of mitochondria were 
acquired as described for whole-cells, except that the DAPI channel was not used.
MITObolome and assembly of metabolite library for absolute quantification—
The high-confidence list of 1,023 human mitochondrial proteins from MitoCarta (Pagliarini 
et al., 2008) was cross-referenced with a list of 2,990 known metabolic enzymes and 
transporters (Birsoy et al., 2015) to give a set of 479 mitochondrial enzymes and 
transporters. For these 479 proteins, KEGG (Kanehisa and Goto, 2000) and manual curation 
was used to identify their cognate substrates, products, and cofactors, which formed a draft 
list of predicted mitochondrial metabolites. Metabolites not listed in KEGG but involved in 
critical mitochondrial processes were added to the draft list as well (e.g., certain 
proteinogenic amino acids are not acted upon by any known enzyme or transporter but are 
needed for mRNA translation in mitochondria). Finally, certain molecules were removed 
because they are not actually metabolites (e.g., carrier proteins conjugated to small 
molecules). Additional modifications, such as removal of metals and non-endogenous 
compounds, were also made to generate the final list of 346 metabolites predicted to be 
present in human mitochondria, which was termed the “MITObolome” (see Table S1 for 
complete list of the added/removed metabolites). Using the MITObolome, a library of 132 
metabolites was assembled to generate standard curves for absolute quantification of 
samples (see Table S1 for complete details).
LC/MS-based metabolomics and quantification of metabolite abundance 
within samples—LC/MS was used to profile and quantify the polar metabolite contents of 
both whole-cell and IP samples. Acetonitrile was Hypergrade and was purchased from EMD 
Millipore. All other solvents were Optima LC/MS grade and were purchased from Thermo 
Fisher Scientific. The metabolite extraction mix was composed of 80% methanol in water, 
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supplemented with a mixture of 17 isotope-labeled amino acids at 90.9 nM each, used as 
internal standards (Cambridge Isotope Laboratories, MSK-A2-1.2).
A library of metabolite chemical standards was curated as described above. Metabolites 
were commercially available and grouped into five pools (see Table S1 for the composition 
of each pool), except that C4- and C5-carnitines were a kind gift of R. Pragani and M. Boxer 
(NCATS, NIH, Rockville, MD) and were synthesized via a published procedure (Goel, Om 
P., SSV Therapeutics, Inc., USA; U.S. Patent Number 7777071, B2; Aug. 17, 2010). 
Standards were validated by using LC/MS to confirm that they contained a robust peak at 
the correct m/z ratio. Stock solutions of each pool, containing 1 mM of each metabolite 
standard in water, were stored at −80°C. On the day of each LC/MS run, these 1 mM stocks 
were used to prepare fresh standard curves diluted with 80% methanol in water containing 
the 17 isotope-labeled internal standards. These standard curves of metabolites within the 
five pools were then analyzed in parallel with each batch of biological samples.
LC/MS-based analyses were performed as described previously (Birsoy et al., 2015) on a 
QExactive benchtop orbitrap mass spectrometer equipped with an Ion Max source and a 
HESI II probe, which was coupled to a Dionex UltiMate 3000 UPLC system (Thermo Fisher 
Scientific). External mass calibration was performed using the standard calibration mixture 
every 7 days. 5 μL of each metabolite sample was injected onto a ZIC-pHILIC 2.1 × 150 
mm (5 μm particle size) column (EMD Millipore). Buffer A was 20 mM ammonium 
carbonate, 0.1% ammonium hydroxide; buffer B was acetonitrile. The chromatographic 
gradient was run at a flow rate of 0.150 mL/minute as follows: 0–20 minutes: linear gradient 
from 80% to 20% B; 20–20.5 minutes: linear gradient from 20% to 80% B; 20.5–28 
minutes: hold at 80% B. The mass spectrometer was operated in full-scan, polarity switching 
mode with the spray voltage set to 3.0 kV, the heated capillary held at 275°C, and the HESI 
probe held at 350°C. The sheath gas flow was set to 40 units, the auxiliary gas flow was set 
to 15 units, and the sweep gas flow was set to 1 unit. The MS data acquisition was 
performed in a range of 70–1000 m/z, with the resolution set at 70,000, the AGC target at 
106, and the maximum injection time at 80 milliseconds.
Metabolite identification and quantification were performed with XCalibur QuanBrowser 
2.2 (Thermo Fisher Scientific) using a 10 ppm mass accuracy window and 0.5 minute 
retention time window. To confirm metabolite identities and to enable quantification, the 
aforementioned pools of authentic metabolite standards were used. Within-batch mass 
deviation was typically < 0.0005 Da, and retention time deviation was < 0.25 minutes. 
Typically, the final concentrations of standards were 1 nM, 10 nM, 100 nM, 1 μM, 10 μM, 
and 30 μM, but pool 4 was run at concentrations of 1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 
300 nM, 1 μM, 3 μM, 10 μM, and 30 μM to more accurately quantify certain metabolites. In 
each sample, the raw peak area for each metabolite was divided by the raw peak area of the 
relevant isotope-labeled internal standard to calculate the relative abundance (see Table S1 
for the internal standard used for each metabolite). Leucine, isoleucine, methionine, proline, 
tyrosine, threonine, histidine, aspartate, glutamate, arginine, phenylalanine, and valine were 
normalized with their isotope-labeled counterparts. All other isotope-labeled amino acids 
were not abundant enough to give robust peaks in every biological sample and were thus not 
used. For determining the relative abundances of all other metabolites, the peak areas were 
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normalized to either isotope-labeled phenylalanine or isotope-labeled valine, depending on 
which isotope-labeled standard had the closer retention time to the metabolite being 
examined. The relative abundances obtained from the standard curve samples were fit to a 
quadratic log-log equation, typically with r2 > 0.99, which was then used to calculate the 
concentration of the metabolite in each metabolite extract. The total number of moles of a 
metabolite in a given whole-cell or IP extract was then calculated from the sample 
concentration and the corresponding sample volume. For undetectable metabolites, 
concentrations were set to 0.
LC/MS matrix effects (e.g., the effects of KPBS on the behavior of metabolites) were 
controlled for by comparing the performance of all 132 metabolites in the quantitative 
profiling library in the presence and absence of KPBS. To model the residual wet volume 
left over after the IP, a surrogate matrix composition of 2 μL of KPBS for every 48 μL of 
80% methanol extraction buffer was used (1/25 dilution). Standard curves were generated 
using either normal 80% methanol/20% water with internal standards (80/20) or 80% 
methanol/20% water with internal standards and with KPBS spiked in at a 1/25 dilution 
(80/20K). Importantly, KPBS did not affect our ability to confidently assign a peak to a 
particular metabolite, as KPBS did not alter the retention time of the metabolites that were 
examined. The standard curves derived from 80/20 samples were then used to calculate the 
concentrations of the 80/20 and 80/20K samples to determine how much deviation there was 
between the two. Based on the median deviation across multiple concentrations of standards 
prepared in 80/20 or 80/20K, a list of correction factors was generated for adjusting the 
quantification of each metabolite within a given IP extract (see Table S1 for correction 
factors).
Measurement of whole-cell concentrations of metabolites—All whole-cell 
metabolite profiling was performed on ice or at 4°C with pre-chilled buffers. Following the 
appropriate treatment, ~2 million HeLa cells expressing HA-MITO were quickly washed 
twice with PBS prepared in Optima LC/MS water and then scraped into 500 μL of 80% 
methanol in water containing the 17 isotope-labeled internal standards. Samples were 
vortexed vigorously for 10 minutes, spun down at 17,000 x g for 10 minutes, and the 
supernatants analyzed with LC/MS as described above to determine the total moles of a 
metabolite in each whole-cell sample.
For each experiment, a replicate set of cells was treated identically and used for measuring 
cell number and volume. The contents of each well were trypsinized and cell number and 
volume measured using a Beckman Z2 Coulter Counter with a size setting of 8–30 μm.
Whole-cell concentrations were calculated using the total moles of a metabolite in a whole-
cell sample, the total number of cells per sample, and the volume of each cell.
Rapid isolation of mitochondria from cells and measurement of matrix 
concentrations of metabolites—Traditional mitochondrial isolation buffer was made of 
75 mM sucrose, 225 mM mannitol, 20 mM HEPES, 0.5 mM EDTA, pH 7.4, cOmplete 
EDTA-free protease inhibitor (Roche) in deionized water. LC/MS-compatible mitochondrial 
isolation buffer, KPBS, was comprised of 136 mM KCl, 10 mM KH2PO4, pH 7.25 in 
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Optima LC/MS water and was prepared using clean equipment and glassware. The pH of the 
buffer was adjusted with KOH because of the sensitivity of isolated mitochondria to sodium. 
After passage through a 0.22 μm filter (Corning), the buffer was kept at 4°C.
For each experiment, an anti-HA IP was performed on HeLa cells expressing Control-MITO 
or HA-MITO. The entire workflow was done on ice in a 4°C cold room with pre-chilled 
buffers and equipment. Only one sample (e.g., Control-MITO or HA-MITO-expressing 
cells) was processed at a time to increase the speed of isolation. 200 μL of anti-HA magnetic 
beads were pre-washed three times with KPBS. All washes were done by gentle pipetting 
using a wide-bore pipette tip and collecting beads using a DynaMag Spin Magnet (Thermo 
Fisher Scientific).
~30 million cells were rapidly washed twice with PBS prepared in Optima LC/MS water and 
then gently scraped into 1 mL KPBS. The cell suspension was spun down at 1000 x g for 2 
minutes, supernatant was discarded, and cell pellet gently resuspended in 1 mL KPBS. Cells 
were homogenized with 25 strokes of a 2 mL dounce homogenizer containing a pure PTFE 
head (VWR International), taking care not to introduce air bubbles into the solution. The 
homogenate was spun down at 1000 x g for 2 minutes and the supernatant incubated with 
200 μL of prewashed beads on an end-over-end rotator for 3.5 minutes. Afterwards, the IP 
was quickly washed twice with 1 mL KPBS, resuspended in 1 mL KPBS, and transferred to 
a new tube. 250 μL of the suspension was taken for detergent lysis and the remainder for 
metabolite extraction. Metabolites were always extracted before detergent lysis. For 
metabolite extraction, beads were collected and incubated for 5 minutes with 50 μL of 80% 
methanol in water containing internal standards. For detergent lysis, beads were collected 
and incubated for 10 minutes with 50 μL of lysis buffer comprised of 50 mM Tris-HCl, pH 
7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, and cOmplete EDTA-free protease 
inhibitor. Afterwards, the detergent lysate and metabolite extract were transferred to new 
tubes, spun down at 17,000 x g for 10 minutes, and the supernatants kept.
In experiments examining the effects of a lengthened workflow on matrix metabolite 
profiles, all steps were identical except that IP samples sat on ice for an additional 4 minutes 
before the final wash solution was aspirated and samples were processed further.
The metabolite extract was analyzed with LC/MS as described earlier to determine the total 
moles of a metabolite in each IP sample. For a metabolite to be considered present at levels 
above background (e.g., to be considered mitochondrial), it had to be at least 1.5-fold more 
abundant in the HA-MITO IP than in the Control-MITO IP across three biological 
replicates. The background-corrected abundance was obtained by subtracting the moles 
present in the Control-MITO IP from those present in the HA-MITO IP.
To determine the corresponding matrix volume for a given HA-MITO IP, a two-part strategy 
was used. First, ~60,000 HA-MITO-expressing cells were cultured under the same 
conditions used for all metabolite profiling experiments, and then fixed, mounted, and 
imaged using the EGFP and DAPI channels. Z-stacks of at least 100 cells per condition were 
generated using a step size of 0.25 μm. The three-dimensional surface of the EGFP signal 
(surface area detail = 0.05 μm, diameter of largest sphere that will fit into object = 0.25 μm) 
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was created with the IMARIS software (Bitplane) and the total mitochondrial volume per 
cell calculated with the built-in volumetric analysis. The mean mitochondrial volume per 
cell in each condition was used for subsequent calculations.
For the second part of our approach, a defined number of HA-MITO-expressing cells were 
lysed as described above. A series of dilutions of this cell lysate was analyzed in parallel 
with HA-MITO IP samples by blotting for citrate synthase, a protein that is predominantly 
localized to the mitochondria within cells (Wiegand and Remington, 1986). Using 
densitometry analysis, the total number of whole-cell equivalents present in each HA-MITO 
IP could be determined. The dilution series behaved linearly with r2 ~ 0.97.
The final matrix volume associated with each HA-MITO IP was then calculated using the 
total mitochondrial volume per cell, the number of whole-cell equivalents present in each 
HA-MITO IP, and the proportion of mitochondrial volume occupied by an orthodox 
configuration of the matrix (~63.16% of mitochondrial volume = matrix) (Gerencser et al., 
2012). Matrix concentrations of metabolites were determined by combining the background-
corrected moles of a metabolite in the HA-MITO IP with the corresponding matrix volume.
Highly-targeted metabolomics—For the highly-targeted analyses of TMRM and TMR 
and certain nucleotide species, the instrument was run as described above, but with the 
following modifications. For TMRM and TMR, an additional tSIM (targeted selected ion 
monitoring) scan in positive ionization mode was done, with the resolution set to 70,000, an 
AGC target of 105, and a maximum integration time of 250 milliseconds. The target masses 
were 401.1860 (corresponding to TMRM) and 387.1703 (corresponding to de-esterified 
TMRM, i.e., TMR). The isolation window around each target mass was set to 1.0 m/z. Only 
relative quantification was done for TMRM and TMR. For the nucleotide analysis, MS data 
was collected in negative ionization mode only, in a mass range of 285–550 m/z, with the 
resolution set to 70,000, an AGC target of 106, and a maximum integration time of 250 
milliseconds.
Untargeted metabolomics—Positive and negative ionization data from LC/MS-based 
analysis of control and HA-MITO IP samples was interrogated with Progenesis CoMet 
software (Nonlinear Dynamics). See Table S1 for complete list of criteria used to determine 
if a metabolite was present at levels above background (e.g., if a metabolite was 
mitochondrial).
Rapid differential centrifugation for isolating mitochondria—For experiments 
isolating mitochondria using rapid differential centrifugation, a modified workflow based on 
existing protocols was used (Bestwick et al., 1982; Bogenhagen and Clayton, 1974). All 
experiments were performed using KPBS to make the isolation conditions of the differential 
centrifugation consistent with those of the IP method. All steps of the centrifugation 
workflow leading up to the post-homogenization spin were identical to those of the IP 
method described above. The homogenate was spun down at 1000 x g for 2 minutes and the 
supernatant taken and spun down at 10,000 x g for 10 minutes. After aspirating the 
supernatant, the pellet was washed with 1 mL of KPBS by gentle resuspension, and then 
transferred to a new tube. The suspension was spun again at 10,000 x g for 10 minutes, after 
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which the supernatant was aspirated and the pellet was incubated with 100 μL lysis buffer 
(see above) for 10 minutes on ice. Afterwards, the detergent lysate was transferred to a new 
tube, spun down at 17,000 x g for 10 minutes, and the supernatant kept. For experiments 
comparing the specificity of differential centrifugation to the IP method, 100 μL of lysis 
buffer was also used to lyse mitochondria isolated by the anti-HA beads.
Calculations for matrix glutamate and aspartate during RC dysfunction in the 
presence and absence of pyruvate—Matrix concentrations from Table S3 were used 
for all calculations. To streamline the explanation of the calculations, the following 
abbreviations will be used: V = vehicle-treated; O = oligomycin-treated; VP = vehicle-
treated, pyruvate-supplemented; OP = oligomycin-treated, pyruvate-supplemented. To 
calculate the pyruvate-driven changes in matrix aspartate during RC dysfunction, the 
following steps were done. Because the concentration of matrix aspartate in VP cells was 
significantly lower than that of V cells (p < 0.05, n = 3), the expected matrix concentration 
of aspartate in OP cells was first calculated by multiplying each replicate of matrix aspartate 
concentrations from VP cells by 0.3014, the average fractional abundance of matrix 
aspartate in O cells relative to V cells. The resulting triplicate set of expected matrix 
concentrations of aspartate in OP cells was significantly different from the measured matrix 
concentrations of aspartate in OP cells (p < 0.05, n = 3). As such, the average expected 
matrix concentration of aspartate (141.85 μM) was subtracted from each replicate of the 
measured matrix concentrations of aspartate in OP cells to obtain a triplicate set of changes 
in matrix aspartate upon pyruvate supplementation during RC dysfunction.
To calculate the pyruvate-driven changes in matrix glutamate during RC dysfunction, the 
following steps were done. The matrix concentrations of glutamate in V and VP cells were 
not significantly different, so it was unnecessary to calculate an expected matrix 
concentration of glutamate for OP cells. Because the matrix glutamate concentrations of O 
and OP cells were significantly different (p < 0.05, n = 3), the average matrix glutamate 
concentration of O cells was subtracted from each replicate of the matrix glutamate 
concentrations of OP cells to give a triplicate set of changes in matrix glutamate upon 
pyruvate supplementation during RC dysfunction.
Heat maps—Heat maps were generated using Java TreeView (Saldanha, 2004). See Tables 
S2 and S3 for complete lists of criteria used to assemble heat maps.
Experimental design—Experiments were not done in a blinded fashion. All instances 
where n replicates are reported had n biological replicates.
QUANTIFICATION AND STATISTICAL ANALYSIS
P-values in the Table S1 panels, “Untargeted pos-measurements” and “Untargeted neg-
measurements,” were calculated using an unpaired, one-tailed, heteroscedastic student’s t-
test in Microsoft Excel. All other p-values were calculated using an unpaired, two-tailed, 
parametric student’s t-test in GraphPad Prism 6, except for the Table S3 panel “Pyruvate’s 
effects – stat. sig.,” for which an identical t-test was performed but in Microsoft Excel rather 
than GraphPad Prism 6. All r2 values were derived from Pearson correlation coefficients 
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calculated in either GraphPad Prism 6 or Microsoft Excel. Principal components analysis 
(Figure 3) and a Pearson correlation matrix of fold-changes in metabolite abundance (Figure 
5) were performed and visualized using R. The exact value of n, the definition of center and 
precision measures, and p-values are provided in all figure legends. The exact values of n 
and p-values for data analyses can also be found in Tables S1 and S3 and certain portions of 
the Methods and Resources. All instances where n replicates are reported had n biological 
replicates.
Measurements of urate are not included in Table S2 “Whole-cell, piericidin” and Table S2 
“Matrix, piericidin” because r2 < 0.99 for the standard curve. Measurements of lactate in IP 
samples are not included in Tables S1–S3 because of the low abundance and resulting poor 
peak quality of lactate in those samples. These exclusions are also detailed in the relevant 
panels of Tables S1–S3.
DATA AND SOFTWARE AVAILABILITY
Data resources—Datasets can be found in Tables S1–S3.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
• A workflow for absolute quantification of mitochondrial matrix 
metabolites
• Rapid and specific isolation of mitochondria from cells for metabolite 
profiling
• Profiling guided by MITObolome, a set of all predicted mitochondrial 
metabolites
• Quantification of >100 metabolites reveals dynamics of mitochondrial 
metabolism
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Figure 1. see also Figure S1: A method for the rapid and specific isolation of intact mitochondria
(A) The 3XTag-EGFP-OMP25 protein properly localizes to mitochondria. Representative 
confocal micrographs of HeLa cells expressing the recombinant EGFP-fusion protein 
(green). Mitochondria and nuclei were stained with MitoTracker Deep Red FM (red) and 
Hoechst (blue), respectively. Scale bars, 10 μm.
(B) Workflow for the absolute quantification of matrix metabolites. Cells expressing 
Control-MITO (Control-MITO cells) or HA-MITO (HA-MITO cells) are rapidly harvested 
and dounce homogenized. HA-tagged mitochondria are isolated with a 3.5 minute IP, 
washed, and then lysed for immunoblot analysis to determine the amount of captured 
mitochondria or extracted for LC/MS-based metabolomics to quantify metabolites. Confocal 
microscopy and volumetric analysis of the HA-MITO-expressing cells are used to determine 
total mitochondrial volume per cell, which is then adjusted based on the percentage of 
mitochondrial volume occupied by the matrix (~63.16% of mitochondrial volume = matrix) 
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(Gerencser et al., 2012). All of these measurements are combined to calculate the matrix 
concentration of a metabolite.
(C) Epitope-tagged mitochondria isolated from cells incubated with MitoTracker Deep Red 
FM retain the dye. Representative confocal micrographs of beads with isolated mitochondria 
(green) and MitoTracker Deep Red FM signal (red). On the right are magnifications of 
several beads with mitochondria. Scale bars, 5 μm.
(D) Purification of epitope-tagged mitochondria has significantly less organellar 
contamination compared to a differential centrifugation method optimized for speed. 
Immunoblot analysis of whole-cell lysates (Whole-cell) and lysates of mitochondria purified 
with anti-HA beads (Anti-HA IP) or differential centrifugation (DC). Lysates were derived 
from cells expressing Control-MITO (Control-MITO cells) or HA-MITO (HA-MITO cells). 
The names of the protein markers used are to the left of the blots and their corresponding 
subcellular compartments to the right. OMM, outer mitochondrial membrane; matrix, 
mitochondrial matrix; Golgi, Golgi complex; ER, endoplasmic reticulum.
(E) Epitope-tagged mitochondria retain both soluble proteins and small molecules to similar 
degrees. A comparison of the amount of captured mitochondria as assessed by a matrix 
protein (Citrate synthase) and a matrix metabolite (Coenzyme A). Data are represented as a 
percentage of the total material present in harvested cells. Cells were cultured in DMEM 
without pyruvate.
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Figure 2. see also Figure S2, Table S1: Identities and concentrations of matrix metabolites in 
human mitochondria
(A) Generation of the MITObolome and the set of 132 metabolites for which concentrations 
were measured. Mitochondrial proteomic data was cross-referenced with a list of all human 
metabolic enzymes and transporters. The overlap between these two data sets was used in 
conjunction with KEGG and manual curation to assemble the MITObolome, a list of all 
predicted metabolites within mitochondria. The MITObolome was filtered on the indicated 
criteria and supplemented with additional metabolites to generate the final set of 132 
metabolites for which concentrations were measured. KEGG, Kyoto Encyclopedia of Genes 
and Genomes.
(B) Absolute quantification of matrix metabolites is highly consistent between experiments. 
Matrix concentrations of metabolites from two biological replicates were compared and a 
Pearson correlation coefficient was calculated.
(C) Concentrations of metabolites in the mitochondrial matrix and whole-cells. Data are 
from cells cultured in DME base media (mean ± SEM, n = 3). For each group, metabolites 
are arranged from most abundant to least abundant within mitochondria. Metabolites not 
considered to be present at levels above background are plotted as red dots on the x-axis. See 
Table S1 for the full names of certain abbreviated metabolites. PPP, pentose phosphate 
pathway.
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Figure 3. see also Table S2: The compartmentalized dynamics of matrix metabolites during RC 
dysfunction
(A) Schematic depicting the function of each RC component and the corresponding sites of 
inhibition for piericidin, antimycin, and oligomycin. Complexes I–IV transfer high- energy 
reducing equivalents from NADH and FADH2 to O2, generating a proton gradient in the 
process. Complex V utilizes this gradient to synthesize ATP. CoQ, coenzyme Q; CytC, 
cytochrome C.
(B) Heat map representing changes in metabolite concentrations upon inhibition of Complex 
I, III, or V, as assessed by whole-cell and mitochondrial metabolomics. For each metabolite 
and inhibitor, the mean log2-transformed fold change is relative to the corresponding whole-
cell or matrix concentration of vehicle-treated cells (n = 3). To be included in the heat map, 
metabolites had to change at least 2-fold upon inhibition of an RC complex. See Table S2 
for additional criteria used to generate this heat map and for the concentrations of all 
metabolites.
(C) Whole-cell and matrix profiles during RC dysfunction are substantially different. 
Principal component analysis of metabolite changes in Figure 3B as assessed by profiling of 
the mitochondrial matrix (blue) or whole-cells (black).
(D) RC inhibition lowers matrix PEP.
(E) RC inhibition increases matrix saccharopine.
(F) The NADH/NAD imbalance during RC dysfunction is more pronounced in the matrix 
than on the whole-cell level.
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(G) The relationship between matrix aspartate and the matrix NADH/NAD ratio can be 
modeled as a power function. Log10-transformed values of matrix aspartate concentrations 
(units of M) and NADH/NAD ratios were compared across different states of RC function 
and a Pearson correlation coefficient was calculated.
(H) Inhibition of Complexes I and III increases matrix GSH/GSSG ratios. For all panels, 
unless indicated otherwise, all experiments were performed in DMEM without pyruvate and 
all measurements are normalized to the corresponding whole-cell or matrix concentrations 
of vehicle-treated cells (mean ± SEM, n = 3, *p < 0.05).
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Figure 4. see also Figure S3: Hallmarks of matrix metabolism under different forms of RC 
inhibition
(A) Matrix acetyl-CoA only accumulates during Complex I inhibition. Data are represented 
as whole-cell or matrix concentrations that have not been normalized.
(B) Complex III dysfunction inhibits the transformation of choline to betaine in the matrix.
(C) Complex V inhibition leads to the accumulation of matrix metabolites at opposite ends 
of the TCA cycle.
(D) The pattern of changes seen in matrix TCA cycle metabolites during Complex V 
inhibition is not recapitulated at the whole-cell level. For all panels, unless indicated 
otherwise, all experiments were performed in DMEM without pyruvate and all 
measurements are normalized to the corresponding whole-cell or matrix concentrations of 
vehicle-treated cells (mean ± SEM, n = 3, *p < 0.05).
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Figure 5. see also Figure S4, Table S3: Amelioration of RC dysfunction with pyruvate increases 
matrix aspartate without restoration of the matrix NADH/NAD ratio
(A) Pyruvate can ameliorate loss of aspartate during Complex V blockade both in whole-
cells and the mitochondrial matrix. All measurements are normalized to the corresponding 
whole-cell or matrix concentrations of vehicle-treated cells.
(B) Pyruvate does not ameliorate matrix NADH/NAD imbalance during Complex V 
dysfunction. Data are presented as NADH/NAD ratios that have not been normalized.
(C) Heat map representing changes in metabolite concentrations upon inhibition of Complex 
V in the presence and absence of pyruvate, as assessed by whole-cell and mitochondrial 
metabolomics. For each metabolite, the mean log2-transformed fold change is relative to the 
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corresponding whole-cell or matrix concentration of vehicle-treated cells in the absence or 
presence of pyruvate (n = 3). To be included in the heat map, metabolites had to change at 
least 2-fold upon inhibition of Complex V. See Table S3 for additional criteria used to 
generate this heat map and for the concentrations of all metabolites.
(D) Pyruvate supplementation has limited effects on the metabolite contents of whole-cells 
and the mitochondrial matrix during Complex V blockade. A Pearson correlation matrix of 
the metabolic changes in Figure 5C.
(E) During Complex V inhibition, pyruvate supplementation leads to a reduction in matrix 
glutamate similar in magnitude to the increase in matrix aspartate. Data are presented as 
matrix concentrations that have not been normalized. See the Methods and Resources for the 
details of these calculations. For all panels, unless indicated otherwise, experiments were 
performed in DMEM with and without pyruvate (1 mM) and measurements are presented as 
the mean ± SEM, n = 3, *p < 0.05.
(F) Model illustrating the effects of pyruvate on cytosolic and matrix aspartate during RC 
dysfunction.
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